#1 Clinical Trials Search in Europe

Cytisinicline

Cytisinicline, also known as cytisine, is an investigational drug being studied in clinical trials for its potential to help people quit smoking. This article summarizes key findings from recent trials examining cytisinicline’s safety, efficacy, and effects on smoking behavior and cravings.

Table of Contents

What is Cytisinicline?

Cytisinicline, also known as cytisine or Tabex, is a medication being studied for its potential to help people quit smoking and vaping[2][9]. It is a plant-based compound that has been used in Eastern Europe for decades to aid in smoking cessation, but is now undergoing clinical trials in the United States and other countries to evaluate its safety and effectiveness[5].

How Does Cytisinicline Work?

Cytisinicline works by targeting specific receptors in the brain called nicotinic acetylcholine receptors, particularly the α4β2 subtype[4]. These are the same receptors that nicotine acts on when a person smokes or vapes. By binding to these receptors, cytisinicline can:

  • Reduce cravings for nicotine
  • Lessen the pleasurable effects of smoking or vaping
  • Alleviate withdrawal symptoms that often occur when trying to quit
This mechanism of action helps make it easier for individuals to stop using tobacco or nicotine-containing e-cigarettes.

Conditions Treated by Cytisinicline

Cytisinicline is primarily being studied for:

  • Smoking Cessation: Helping people quit smoking traditional cigarettes[1]
  • Vaping Cessation: Assisting individuals in stopping the use of e-cigarettes or vaping devices[2]
These conditions are often referred to as Tobacco Use Disorder when diagnosed by healthcare professionals[4].

Dosage and Administration

In most clinical trials, cytisinicline is being tested as an oral medication in the form of tablets or capsules. The typical dosage being studied is:

  • 3 mg taken three times daily (abbreviated as TID)[6]
  • Treatment duration ranging from 6 to 12 weeks[7]
It’s important to note that the optimal dosage and duration may vary depending on individual needs and the results of ongoing studies. Always follow the guidance of a healthcare professional when taking any medication.

Effectiveness of Cytisinicline

Several clinical trials are currently evaluating the effectiveness of cytisinicline for smoking and vaping cessation. Researchers are measuring:

  • The proportion of participants who achieve smoking or vaping abstinence during treatment[6]
  • Continuous abstinence rates after treatment completion[7]
  • Relapse rates and long-term success in quitting[6]
While final results are still pending for many studies, early research suggests that cytisinicline may be an effective aid for those trying to quit smoking or vaping.

Safety and Side Effects

The safety profile of cytisinicline is being closely monitored in clinical trials. Some studies are specifically designed to evaluate:

  • Treatment-emergent adverse events (side effects that occur after starting the medication)[5]
  • Effects on heart rhythm and other cardiac parameters[8]
  • How the medication is processed by the body, especially in people with kidney problems[3]
As with any medication, cytisinicline may cause side effects. The full range of potential side effects is still being studied, and patients in clinical trials are closely monitored for any adverse reactions.

Ongoing Research on Cytisinicline

Cytisinicline is the subject of numerous ongoing clinical trials, including:

  • Studies comparing its effectiveness to placebo (a dummy pill with no active ingredient)[6]
  • Investigations into how food affects the absorption of the medication[10]
  • Research on its effects on brain activity related to smoking cues[4]
  • Evaluations of its potential for long-term use in preventing relapse[7]
These studies aim to provide a comprehensive understanding of cytisinicline’s benefits, risks, and optimal use in helping people quit smoking and vaping.

Aspect Details
Drug Name Cytisinicline (also known as cytisine)
Primary Use Smoking cessation
Mechanism of Action Targets α4β2 nicotinic acetylcholine receptors
Dosage in Trials Typically 3 mg three times daily
Treatment Duration 6 to 12 weeks in most studies
Primary Outcomes Smoking abstinence rates, verified by exhaled carbon monoxide levels
Secondary Outcomes Continuous abstinence, relapse rates, craving reduction
Safety Assessments Adverse events, vital signs, ECG changes, laboratory tests
Ongoing Research Long-term efficacy, effects on neural substrates of cue-reactivity, use in special populations (e.g., renal impairment)

FAQ

  • What is cytisinicline? Cytisinicline is an investigational drug being studied as a potential treatment to help people quit smoking. It targets nicotinic acetylcholine receptors in the brain that are involved in nicotine addiction.
  • How is cytisinicline taken? In clinical trials, cytisinicline is typically taken as oral tablets, usually 3 mg three times daily. The treatment duration ranges from 6 to 12 weeks in most studies.
  • What are the potential benefits of cytisinicline for smoking cessation? Clinical trials have shown that cytisinicline may help increase smoking abstinence rates compared to placebo. It appears to reduce cigarette cravings and withdrawal symptoms in some participants.
  • Are there any side effects of cytisinicline? As with any medication, cytisinicline may cause side effects. Clinical trials are evaluating its safety profile. Common side effects observed so far include nausea, sleep disturbances, and abnormal dreams. Serious side effects appear to be rare but are still being studied.
  • How does cytisinicline compare to other smoking cessation aids? While direct comparisons are limited, early results suggest cytisinicline may be as effective as some existing smoking cessation medications. However, more research is needed to fully understand how it compares in terms of efficacy and side effects.

Ongoing Clinical Trials on Cytisinicline

  • Study Comparing Cytisinicline and Nicotine Therapy for Patients with Nicotine Dependence and Chronic Kidney Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • A study to evaluate how cytisinicline works in patients with nicotine addiction and kidney problems or those undergoing dialysis

    Not recruiting

    1 1 1
    Investigated drugs:
    Portugal Spain

  • A study to evaluate how food affects the absorption of cytisinicline in healthy adult smokers

    Not recruiting

    1 1 1
    Investigated drugs:
    Portugal

  • Study of cytisinicline and moxifloxacin effects on heart electrical activity in healthy smokers with nicotine addiction

    Not recruiting

    1 1 1
    Investigated drugs:
    Portugal

Glossary

  • Cytisinicline: An investigational drug being studied for smoking cessation that targets nicotinic acetylcholine receptors in the brain.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Carbon monoxide (CO): A gas produced when smoking tobacco, often measured in exhaled breath to verify smoking abstinence.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • QT interval: A measurement on an electrocardiogram that represents the time for electrical activation and inactivation of the ventricles of the heart.
  • Abstinence: The act of refraining from smoking cigarettes.
  • Craving: A strong desire or urge to smoke cigarettes.
  • Relapse: Returning to smoking after a period of abstinence.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT06579846
  2. https://clinicaltrials.gov/study/NCT06435221
  3. https://clinicaltrials.gov/study/NCT05631938
  4. https://clinicaltrials.gov/study/NCT06617312
  5. https://clinicaltrials.gov/study/NCT03848208
  6. https://clinicaltrials.gov/study/NCT05206370
  7. https://clinicaltrials.gov/study/NCT04576949
  8. https://clinicaltrials.gov/study/NCT05566288
  9. https://clinicaltrials.gov/study/NCT05431387
  10. https://clinicaltrials.gov/study/NCT05981768